Claims
- 1. A vaccine composition comprising a live Herpes Simplex Virus-2 wherein the protein kinase domain of ICP10 (SEQ ID NO:2) has been deleted, and a pharmaceutically acceptable carrier or diluent.
- 2. A method of immunizing a subject against Herpes Simplex Virus-2 comprising adminstering to said subject the vaccine composition of claim 1.
- 3. A method of confering immunity against HSV-2 in a subject comprising administering the vaccine composition of claim 1.
- 4. A method of preventing clinical symptoms in a subject associated with Herpes Simplex Virus-2 comprising administering the vaccine composition of claim 1.
- 5. The method of claim 2, 3, or 4 wherein said subject is a human.
- 6. The method of claim 5 wherein the dosage range for said vaccine is 1 to 100 million pfu.
- 7. The method of claim 5 wherein said vaccine composition is administered via an intranasal, oral, intravaginal, or subcutaneous route.
- 8. The method of claim 6 wherein the dosage range for said vaccine is 1000 to 75 million pfu.
- 9. The method claim 6 wherein the dosage range for said vaccine is 10,000 to 50 million pfu.
Parent Case Info
This application claims priority to U.S. Provisional Patent Application Ser. No. 60/029,093, filed Oct. 22, 1996.
Non-Patent Literature Citations (3)
Entry |
Parr et al. Labrotory Investigation. 1994, vol. 70, No. 3, pp. 369-380. |
Milligan et al. Virology, 1995, vol. 206, pp. 234-241. |
Murthy et al. Journal of Virology, 1989, vol. 63, No. 8, pp. 3307-3314. |